Rockefeller Capital Management
BBIO icon

Rockefeller Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Rockefeller Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.38M Sell
45,317
-8,304
-15% -$582K 0.01% 1141
2026
Q1 		$3.98M Buy
53,621
+15,192
+40% +$1.1M 0.01% 1012
2025
Q4 		$2.94M Buy
38,429
+25,169
+190% +$1.65M 0.01% 1084
2025
Q3 		$689K Sell
13,260
-25,506
-66% -$1.24M ﹤0.01% 1615
2025
Q2 		$1.67M Buy
38,766
+21,531
+125% +$783K ﹤0.01% 1170
2025
Q1 		$596K Sell
17,235
-24,054
-58% -$811K ﹤0.01% 1431
2024
Q4 		$1.13M Buy
41,289
+30
+0.1% +$775 ﹤0.01% 1202
2024
Q3 		$1.05M Buy
41,259
+4,317
+12% +$113K ﹤0.01% 1211
2024
Q2 		$936K Sell
36,942
-4,070
-10% -$111K ﹤0.01% 1228
2024
Q1 		$1.27M Sell
41,012
-480
-1% -$16.3K ﹤0.01% 1176
2023
Q4 		$1.68M Sell
41,492
-700
-2% -$21K 0.01% 977
2023
Q3 		$1.11M Sell
42,192
-16,278
-28% -$462K ﹤0.01% 1046
2023
Q2 		$1.01M Buy
58,470
+9,268
+19% +$139K ﹤0.01% 1079
2023
Q1 		$815K Buy
49,202
+3,885
+9% +$45.3K ﹤0.01% 1148
2022
Q4 		$345K Sell
45,317
-5,046
-10% -$48.3K ﹤0.01% 1418
2022
Q3 		$500K Sell
50,363
-16,476
-25% -$171K ﹤0.01% 1268
2022
Q2 		$606K Sell
66,839
-23,449
-26% -$196K ﹤0.01% 1185
2022
Q1 		$915K Sell
90,288
-1,018,945
-92% -$10.5M ﹤0.01% 1085
2021
Q4 		$18.5M Buy
1,109,233
+272,319
+33% +$11.5M 0.09% 232
2021
Q3 		$39.2M Buy
836,914
+4,830
+0.6% +$259K 0.21% 119
2021
Q2 		$50.7M Buy
832,084
+12,452
+2% +$711K 0.29% 79
2021
Q1 		$50.5M Buy
819,632
+42,601
+5% +$2.79M 0.34% 66
2020
Q4 		$55.3M Buy
+777,031
New +$37.5M 0.42% 51

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Rockefeller Capital Management's BBIO Position: Q2 2026 in Review

Rockefeller Capital Management reduced its BridgeBio Pharma (BBIO) stake by 15% in Q2 2026, selling an estimated $582K and leaving 45,317 shares worth $3.38M. The position accounts for 0.01% of the portfolio, ranked #1141.

Rockefeller Capital Management first reported a position in BBIO in Q4 2020 and has held it in 23 quarters since. The position peaked at $55.3M in Q4 2020. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Rockefeller Capital Management held 45,317 shares of BridgeBio Pharma worth $3.38M as of Q2 2026.
  • Rockefeller Capital Management sold 8,304 BridgeBio Pharma shares in Q2 2026, an estimated $582K.
  • BridgeBio Pharma made up 0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1141 holding.
  • Rockefeller Capital Management first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 23 quarters since.
  • Rockefeller Capital Management's BridgeBio Pharma position peaked at $55.3M in Q4 2020.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.